Anti-inflammatory peptides and composition comprising the same

US10039811B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10039811-B2
Application numberUS-201615343502-A
CountryUS
Kind codeB2
Filing dateNov 4, 2016
Priority dateMay 11, 2012
Publication dateAug 7, 2018
Grant dateAug 7, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating a variety of different types of inflammatory diseases.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for treating a respiratory disease comprising administering to a subject in need thereof a composition comprising the isolated peptide of SEQ ID NO: 1. 2. The method according to claim 1 , wherein the respiratory disease is selected from the group consisting of asthma; epiglottitis; bronchitis; emphysema; rhinitis; cystic fibrosis; interstitial pneumonitis; COPD (chronic obstructive pulmonary disease); adult respiratory distress syndrome; coniosis; alveolitis; bronchiolitis; pharyngitis; pleurisy; and sinusitis. 3. The method of claim 1 , wherein the composition is administered through oral, rectal, transdermal, intravenous, intramuscular, intraperitoneal, in the bone marrow, epidural, or subcutaneous means. 4. The method of claim 1 , wherein the composition comprises 0.1 μg/mg to 1 mg/mg of the isolated peptide. 5. The method according to claim 1 , wherein the peptide is administered in a single dose at a concentration of 0.1 μg/kg to 1.0 g/kg. 6. The method according to claim 1 , wherein the peptide is administered in a single dose at a concentration of 1 μg/kg to 10 mg/kg. 7. The method according to claim 1 , wherein the peptide is administered 1 to 3 times a day. 8. The method of claim 1 , wherein the peptide is administered at a daily dose of 0.1 μg/kg to 1.0 g/kg. 9. The method of claim 8 , wherein the peptide is administered 1 to 3 times daily.

Assignees

Inventors

Classifications

  • Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

  • Immunosuppressants, e.g. drugs for graft rejection · CPC title

  • Immunomodulators · CPC title

  • Drugs for disorders of the cardiovascular system · CPC title

  • Antineoplastic agents · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10039811B2 cover?
A peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequenc…
Who is the assignee on this patent?
Gemvax & Kael Co Ltd, Kim Sang Jae
What technology area does this patent fall under?
Primary CPC classification A61K38/45. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).